Scolaris Content Display Scolaris Content Display

Comparison 1 Antithrombin versus Control, Outcome 1 Neonatal Mortality.
Figuras y tablas -
Analysis 1.1

Comparison 1 Antithrombin versus Control, Outcome 1 Neonatal Mortality.

Comparison 1 Antithrombin versus Control, Outcome 2 Mortality within 7 days.
Figuras y tablas -
Analysis 1.2

Comparison 1 Antithrombin versus Control, Outcome 2 Mortality within 7 days.

Comparison 1 Antithrombin versus Control, Outcome 3 Mortality before discharge.
Figuras y tablas -
Analysis 1.3

Comparison 1 Antithrombin versus Control, Outcome 3 Mortality before discharge.

Comparison 1 Antithrombin versus Control, Outcome 4 IVH Grade 1‐3 after 1 week.
Figuras y tablas -
Analysis 1.4

Comparison 1 Antithrombin versus Control, Outcome 4 IVH Grade 1‐3 after 1 week.

Comparison 1 Antithrombin versus Control, Outcome 5 IVH Grade 3 after 1 week.
Figuras y tablas -
Analysis 1.5

Comparison 1 Antithrombin versus Control, Outcome 5 IVH Grade 3 after 1 week.

Comparison 1 Antithrombin versus Control, Outcome 6 PVED (grade 4 IVH) after 1 week.
Figuras y tablas -
Analysis 1.6

Comparison 1 Antithrombin versus Control, Outcome 6 PVED (grade 4 IVH) after 1 week.

Comparison 1 Antithrombin versus Control, Outcome 7 Patients needing surfactant.
Figuras y tablas -
Analysis 1.7

Comparison 1 Antithrombin versus Control, Outcome 7 Patients needing surfactant.

Comparison 1 Antithrombin versus Control, Outcome 8 Patients with pneumothorax.
Figuras y tablas -
Analysis 1.8

Comparison 1 Antithrombin versus Control, Outcome 8 Patients with pneumothorax.

Comparison 1 Antithrombin versus Control, Outcome 9 Patients needing inotropes.
Figuras y tablas -
Analysis 1.9

Comparison 1 Antithrombin versus Control, Outcome 9 Patients needing inotropes.

Comparison 1 Antithrombin versus Control, Outcome 10 Patients with PDA.
Figuras y tablas -
Analysis 1.10

Comparison 1 Antithrombin versus Control, Outcome 10 Patients with PDA.

Comparison 1 Antithrombin versus Control, Outcome 11 Patients with pulmonary hemorrhage.
Figuras y tablas -
Analysis 1.11

Comparison 1 Antithrombin versus Control, Outcome 11 Patients with pulmonary hemorrhage.

Comparison 1 Antithrombin versus Control, Outcome 12 Clinical apparent bleeding during the first week of life.
Figuras y tablas -
Analysis 1.12

Comparison 1 Antithrombin versus Control, Outcome 12 Clinical apparent bleeding during the first week of life.

Comparison 1 Antithrombin versus Control, Outcome 13 Bronchopulmonary dysplasia.
Figuras y tablas -
Analysis 1.13

Comparison 1 Antithrombin versus Control, Outcome 13 Bronchopulmonary dysplasia.

Comparison 1. Antithrombin versus Control

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Neonatal Mortality Show forest plot

1

122

Risk Ratio (M‐H, Fixed, 95% CI)

3.5 [0.76, 16.18]

2 Mortality within 7 days Show forest plot

2

182

Risk Ratio (M‐H, Fixed, 95% CI)

2.67 [0.72, 9.83]

3 Mortality before discharge Show forest plot

1

122

Risk Ratio (M‐H, Fixed, 95% CI)

2.33 [0.63, 8.61]

4 IVH Grade 1‐3 after 1 week Show forest plot

2

182

Risk Ratio (M‐H, Fixed, 95% CI)

1.27 [0.79, 2.05]

5 IVH Grade 3 after 1 week Show forest plot

2

182

Risk Ratio (M‐H, Fixed, 95% CI)

0.9 [0.39, 2.10]

6 PVED (grade 4 IVH) after 1 week Show forest plot

1

122

Risk Ratio (M‐H, Fixed, 95% CI)

1.17 [0.42, 3.27]

7 Patients needing surfactant Show forest plot

1

60

Risk Ratio (M‐H, Fixed, 95% CI)

1.04 [0.89, 1.21]

8 Patients with pneumothorax Show forest plot

1

60

Risk Ratio (M‐H, Fixed, 95% CI)

0.67 [0.12, 3.71]

9 Patients needing inotropes Show forest plot

1

60

Risk Ratio (M‐H, Fixed, 95% CI)

0.67 [0.21, 2.13]

10 Patients with PDA Show forest plot

1

60

Risk Ratio (M‐H, Fixed, 95% CI)

1.07 [0.65, 1.74]

11 Patients with pulmonary hemorrhage Show forest plot

1

60

Risk Ratio (M‐H, Fixed, 95% CI)

0.75 [0.18, 3.07]

12 Clinical apparent bleeding during the first week of life Show forest plot

1

122

Risk Ratio (M‐H, Fixed, 95% CI)

1.23 [0.89, 1.71]

13 Bronchopulmonary dysplasia Show forest plot

1

60

Risk Ratio (M‐H, Fixed, 95% CI)

1.25 [0.37, 4.21]

Figuras y tablas -
Comparison 1. Antithrombin versus Control